ScholarLens Back to search
2007•Chinese Journal of Clinical Oncology and RehabilitationRequires access

Treatment and survival analysis of 57 cases of inoperable stage-III non-small cell lung cancer

Gang Chen

Open publisher page 0 citations

Abstract

Objective To observe the clinical efficacy of different treatments in inoperable stage-Ⅲ non-small cell lung cancer(NSCLC) and their influence on prognosis.Methods Thirty-six cases(9 cases stage ⅢA and 27 cases stage ⅢB) were given intravenous chemotherapy and radiotherapy(group A),and other 21 cases(5 cases stage ⅢA and 16 cases stage ⅢB) were given BAI(bronchial artery infusion) combined with intravenous chemotherapy and radiotherapy(group B).Results The median time to progression in group A and group B was 12.0 and 11.75 months respectively(P=0.74).The median survival time of group A and group B was 17.96 and 18.33 months respectively(P=0.461).The one-,two-and three-years survival rates of group A and group B were 75.0%,29.1%,11.7% and 76.2%,23.8%,4.8% respectively(P0.05).Conclusion On the basis of intravenous chemotherapy and radiotherapy,BAI cannot significantly improve the long-term survival of inoperable stage-Ⅲ NSCLC.

About this research paper

What this paper is about

Objective To observe the clinical efficacy of different treatments in inoperable stage-Ⅲ non-small cell lung cancer(NSCLC) and their influence on prognosis.Methods Thirty-six cases(9 cases stage ⅢA and 27 cases stage ⅢB) were given intravenous chemotherapy and radiotherapy(group A),and other 21 cases(5 cases stage ⅢA and 16 cases stage ⅢB) were given BAI(bronchial artery infusion) combined with intravenous chemotherapy and radiotherapy(group B).Results The median time to progression in group A and group B was 12.0 and 11.75 months respectively(P=0.74).The median survival time of group A and group B was 17.96 and 18.33 months respectively(P=0.461).The one-,two-and three-years survival rates of group A and group B were 75.0%,29.1%,11.7% and 76.2%,23.8%,4.8% respectively(P0.05).Conclusion On the basis of intravenous chemotherapy and radiotherapy,BAI cannot significantly improve the long-term survival of inoperable stage-Ⅲ NSCLC.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To observe the clinical efficacy of different treatments in inoperable stage-Ⅲ non-small cell lung cancer(NSCLC) and their influence on prognosis.Methods Thirty-six cases(9 cases stage ⅢA and 27 cases stage ⅢB) were given intravenous chemotherapy and radiotherapy(group A),and other 21 cases(5 cases stage ⅢA and 16 cases stage ⅢB) were given BAI(bronchial artery infusion) combined with intravenous chemotherapy and radiotherapy(group B).Results The median time to progression in group A and group B was 12.0 and 11.75 months respectively(P=0.74).The median survival time of group A and group B was 17.96 and 18.33 months respectively(P=0.461).The one-,two-and three-years survival rates of group A and group B were 75.0%,29.1%,11.7% and 76.2%,23.8%,4.8% respectively(P0.05).Conclusion On the basis of intravenous chemotherapy and radiotherapy,BAI cannot significantly improve the long-term survival of inoperable stage-Ⅲ NSCLC.

Key concepts: Medicine, Stage (stratigraphy), Group B, Chemotherapy, Radiation therapy, Group A, Lung cancer, Internal medicine

Back to paper searchBrowse research topicsOriginal source
Treatment and survival analysis of 57 cases of inoperable stage-III non-small cell lung cancer — Research Paper | ScholarLens